6533b823fe1ef96bd127e331
RESEARCH PRODUCT
Large Between-Patient Variability in eGFR Decline before Clinical Trial Enrollment and Impact on Atrasentan’s Efficacy:
Hans-henrik ParvingJosé Luis GórrizSydney C.w. TangMichele ProvenzanoLuca De NicolaSimke W. WaijerDick De ZeeuwJulio PascualChristoph WannerRobert S. BuschRon T. GansevoortDi XieFan Fan HouSieta T. De VriesPablo E. PergolaPhilippe ZaouiGozewijn D. LavermanHiddo J.l. Heerspinksubject
Oncologymedicine.medical_specialtyMEDLINEeGFR declineType 2 diabetesEgfr declineendothelin receptor antagonistlaw.inventionRandomized controlled triallawInternal medicinePost-hoc analysismedicinebusiness.industryEndothelin receptor antagonistAtrasentan22/2 OA procedureGeneral Medicinemedicine.diseaseClinical trialNephrologyrandomized controlled trialtype 2 diabetesbusinesschronic kidney diseasemedicine.drugdescription
n/a.
year | journal | country | edition | language |
---|---|---|---|---|
2021-11-01 | Journal of the American Society of Nephrology |